全文获取类型
收费全文 | 1695628篇 |
免费 | 126637篇 |
国内免费 | 3797篇 |
专业分类
耳鼻咽喉 | 21750篇 |
儿科学 | 55683篇 |
妇产科学 | 46168篇 |
基础医学 | 241477篇 |
口腔科学 | 48825篇 |
临床医学 | 151575篇 |
内科学 | 334227篇 |
皮肤病学 | 38696篇 |
神经病学 | 131337篇 |
特种医学 | 64016篇 |
外国民族医学 | 242篇 |
外科学 | 258006篇 |
综合类 | 38960篇 |
现状与发展 | 4篇 |
一般理论 | 531篇 |
预防医学 | 124295篇 |
眼科学 | 40250篇 |
药学 | 123884篇 |
7篇 | |
中国医学 | 4482篇 |
肿瘤学 | 101647篇 |
出版年
2021年 | 12857篇 |
2019年 | 13593篇 |
2018年 | 20039篇 |
2017年 | 15284篇 |
2016年 | 16674篇 |
2015年 | 19037篇 |
2014年 | 26298篇 |
2013年 | 38039篇 |
2012年 | 52886篇 |
2011年 | 55604篇 |
2010年 | 32867篇 |
2009年 | 30769篇 |
2008年 | 51672篇 |
2007年 | 54976篇 |
2006年 | 55414篇 |
2005年 | 52725篇 |
2004年 | 50909篇 |
2003年 | 48326篇 |
2002年 | 46520篇 |
2001年 | 91896篇 |
2000年 | 93711篇 |
1999年 | 77043篇 |
1998年 | 19762篇 |
1997年 | 17298篇 |
1996年 | 17428篇 |
1995年 | 16770篇 |
1994年 | 15311篇 |
1993年 | 14089篇 |
1992年 | 57414篇 |
1991年 | 55310篇 |
1990年 | 53009篇 |
1989年 | 50792篇 |
1988年 | 46164篇 |
1987年 | 44962篇 |
1986年 | 42251篇 |
1985年 | 40015篇 |
1984年 | 29365篇 |
1983年 | 24922篇 |
1982年 | 13908篇 |
1979年 | 25551篇 |
1978年 | 17587篇 |
1977年 | 14925篇 |
1976年 | 13878篇 |
1975年 | 14569篇 |
1974年 | 17645篇 |
1973年 | 16954篇 |
1972年 | 15686篇 |
1971年 | 14467篇 |
1970年 | 13439篇 |
1969年 | 12527篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
Clinical & Experimental Metastasis - 相似文献
13.
14.
15.
Keiko Goto Yutaka Fujiwara Takeshi Isobe Naoko Chayahara Naomi Kiyota Toru Mukohara Yukari Tsubata Takamasa Hotta Kenji Tamura Noboru Yamamoto Hironobu Minami 《Cancer science》2019,110(6):1987-1994
Although dose reduction of S‐1 is recommended for patients with impaired renal function, dose modification for such patients has not been prospectively evaluated. The aim of the present study was to investigate the pharmacokinetic parameters of 5‐fluorouracil, 5‐chloro‐2,4 dihydroxypyridine and oteracil potassium, and to review the recommended dose modification of S‐1 in patients with renal impairment. We classified patients receiving S‐1 into 4 groups according to their renal function, as measured using the Japanese estimated glomerular filtration rate (eGFR) equation. The daily S‐1 dose was adjusted based on the patient's eGFR and body surface area. Blood samples were collected for pharmacokinetic analysis. A total of 33 patients were enrolled and classified into 4 groups as follows: 10 patients in cohort 1 (eGFR ≥ 80 mL/min/1.73 m2), 10 patients in cohort 2 (eGFR = 50‐79 mL/min/1.73 m2), 10 patients in cohort 3 (eGFR = 30‐49 mL/min/1.73 m2), and 3 patients in cohort 4 (eGFR < 30 mL/min/1.73 m2). Those in cohorts 3 and 4 treated with an adjusted dose of S‐1 showed a similar area under the curve for 5‐fluorouracil (941.9 ± 275.6 and 1043.5 ± 224.8 ng/mL, respectively) compared with cohort 2 (1034.9 ± 414.3 ng/mL). Notably, while there was a statistically significant difference between cohort 1 (689.6 ± 208.8 ng/mL) and 2 (P = 0.0474) treated with an equal dose of S‐1, there was no significant difference observed in the toxicity profiles of the cohorts. In conclusion, dose adjustment of S‐1 in patients with impaired renal function using eGFR is appropriate and safe. 相似文献
16.
Adjuvant irradiation is the standard treatment after breast conservative surgery. Normofractionated regimen with an overall treatment time of 5 to 6 weeks is often considered as a limiting factor for irradiation compliance. In order to answer this issue, moderate and more recently extreme hypofractionated protocols appeared. We report here oncological outcomes and toxicity of hypofractionated breast irradiation. After defining the frame of moderate and extreme hypofractionated breast irradiations based on overall treatment time, patient selection criteria were listed. According to their levels of proof, the results of moderate and extreme hypofractionated breast irradiation were analysed. Overall treatment time for moderate hypofractionated breast irradiation ranged from 3 to 4 weeks, while for extreme hypofractionated breast irradiation, it was less than 1 week. For moderate hypofractionated breast irradiation, whole breast irradiation was currently performed with or without lymph node irradiation. Moderate hypofractionated breast irradiation has proven to be as safe and as efficient as normofractionated breast irradiation with level IA evidence. For extreme hypofractionated breast irradiation, phase III randomized trials confirmed that accelerated partial breast irradiation was non-inferior in terms of local control compared to normofractionated whole breast irradiation (with external beam radiation therapy and multicatheter brachytherapy), with similar acute and late toxicity. While the use of intraoperative breast irradiation remains under debate, new very accelerated partial breast irradiation (overall treatment time not exceeding 2 days) protocols emerged with encouraging results. Accelerated partial breast irradiation is warranted for extreme hypofractionated breast irradiation and is indicated for low-risk breast cancers. Moderate and extreme hypofractionated breast irradiation regimens are validated and can be routinely proposed according to patient selection criteria. 相似文献
17.
18.
19.
20.